Press Room

Article / Oct 26, 2018

The Coming of Age of Amorphous Solid Dispersions

Pharma's Almanac, 26 October, 2018

Although the majority of new drug candidates suffer from poor solubility and bioavailability, oral solid dosage forms remain the preferred route of administration due to their ease of use and convenience for patients and caregivers. In recent years, numerous drugs formulated as amorphous solid dispersions (ASDs) have been successfully commercialized, confirming the effectiveness of these technologies for enhancing the dissolution of challenging APIs.

Read the full article

Topics covered in the article:

  • Focus on Spray Drying

  • Addressing Solubility Issues

  • Benefits of ASDs

  • Two Leading ASD Technologies

  • Maintaining the Metastable Form

  • Dealing with Brick Dust

  • Facilitating ASD Development and Manufacturing

  • Greater Understanding for Rational Design

Read the full article

Also in the Press Room

News / Sep 17, 2021

World Patient Safety Day 2021

Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.